Specific assay for active demyelinization
US4136160A · kind A · utility
Inventor
Key dates
| Filing date | Aug 17, 1977 |
| Grant date | Jan 23, 1979 |
| Priority date | — |
| Expiry date | Aug 17, 1997 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/811
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A specific test for active demyelinzation is based on a discovery that free myelin basic protein can be detected in cerebrospinal fluid by the use of a radioimmunoassay, and that the level of basic protein found corresponds to the activity of demyelinating pathologies. A simple method is utilized, wherein samples of cerebrospinal fluid are assayed and the results of the assay are compared with standard samples of myelin basic protein. Patients with active demyelinating diseases have high levels (17-100ng/ml) of basic protein; those with progressive pathologies have less (6-16 ng/ml); and those in remission have less than 4 ng/ml, comparable to the control population.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.